AYTU BIOSCIENCE ($AYTU) posted quarterly earnings results on Wednesday, May 14th. The company reported earnings of $0.20 per share, beating estimates of -$0.17 by $0.37. The company also reported revenue of $18,450,000, beating estimates of $14,013,780 by $4,436,220.
You can see Quiver Quantitative's $AYTU stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AYTU BIOSCIENCE Insider Trading Activity
AYTU BIOSCIENCE insiders have traded $AYTU stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AYTU stock by insiders over the last 6 months:
- JOSHUA R. DISBROW (Chief Executive Officer) purchased 15,000 shares for an estimated $19,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AYTU BIOSCIENCE Hedge Fund Activity
We have seen 12 institutional investors add shares of AYTU BIOSCIENCE stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STONEPINE CAPITAL MANAGEMENT, LLC removed 93,409 shares (-18.6%) from their portfolio in Q4 2024, for an estimated $158,795
- ARMISTICE CAPITAL, LLC removed 86,000 shares (-36.4%) from their portfolio in Q4 2024, for an estimated $146,200
- JAFFETILCHIN INVESTMENT PARTNERS, LLC added 17,437 shares (+inf%) to their portfolio in Q1 2025, for an estimated $20,924
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 14,865 shares (+inf%) to their portfolio in Q1 2025, for an estimated $17,838
- NORTHERN TRUST CORP removed 14,557 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $24,746
- TWO SIGMA SECURITIES, LLC added 11,690 shares (+inf%) to their portfolio in Q4 2024, for an estimated $19,873
- GEODE CAPITAL MANAGEMENT, LLC added 11,211 shares (+26.2%) to their portfolio in Q1 2025, for an estimated $13,453
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
